Alterity Therapeutics Ltd (ATHE)
NASDAQ:ATHE
Top Page
Alterity Therapeutics
(NASDAQ:ATHE)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.00
▼(-15.49% Downside)
Action:ReiteratedDate:02/07/26
The score is primarily held back by persistent unprofitability and negative operating/free cash flow despite strong gross margins and solid recent revenue growth. Technicals are mixed—some near-term strength above shorter moving averages, but weaker longer-term trend signals—and valuation is constrained by negative earnings and no dividend support.
Positive Factors
High gross margins
Sustained gross margins above 90% indicate a structurally favorable cost base relative to revenue. For a biotech, very high gross margins provide flexibility to fund R&D and absorb fixed development costs as revenues scale, improving long-term operating leverage if commercial traction continues.
Negative Factors
Negative operating and free cash flow
Persistent negative operating and free cash flows create a structural funding requirement to progress clinical programs. Over a multi‑month horizon, this increases reliance on dilutive equity raises or partnerships, which can constrain strategic optionality and delay program timelines if financing terms deteriorate.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained gross margins above 90% indicate a structurally favorable cost base relative to revenue. For a biotech, very high gross margins provide flexibility to fund R&D and absorb fixed development costs as revenues scale, improving long-term operating leverage if commercial traction continues.
Read all positive factors
Alterity Therapeutics (ATHE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$61.47M
Dividend YieldN/A
Average Volume (3M)13.05K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue GrowthN/A
EPS Growth63.85%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.38
Shares Outstanding18,125,694
10 Day Avg. Volume16,981
30 Day Avg. Volume13,055
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.56
Price to Sales (P/S)12.18
P/FCF Ratio-5.79
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue12.74
Enterprise Value/Gross Profit13.16
Enterprise Value/Ebitda-2.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$3.88M
Alterity Therapeutics Business Overview & Revenue Model
Company Description
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is A...
How the Company Makes Money
null...
Alterity Therapeutics Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.83M | 5.44M | 4.02M | 3.92M | 5.12M | 4.34M |
| Gross Profit | 3.71M | 5.31M | 3.80M | 3.63M | 4.76M | 3.98M |
| EBITDA | -19.87M | -14.63M | -19.57M | -14.60M | -17.39M | -15.16M |
| Net Income | -14.41M | -12.15M | -19.12M | -13.81M | -12.85M | -15.31M |
Balance Sheet | ||||||
| Total Assets | 56.86M | 46.03M | 19.22M | 27.32M | 41.36M | 33.59M |
| Cash, Cash Equivalents and Short-Term Investments | 49.15M | 40.66M | 12.64M | 15.77M | 34.81M | 28.12M |
| Total Debt | 98.35K | 155.46K | 159.04K | 210.38K | 117.49K | 65.65K |
| Total Liabilities | 2.65M | 3.62M | 5.43M | 4.50M | 5.89M | 3.12M |
| Stockholders Equity | 54.21M | 42.40M | 13.80M | 22.81M | 35.47M | 30.47M |
Cash Flow | ||||||
| Free Cash Flow | -2.36M | -11.45M | -12.61M | -20.04M | -12.43M | -17.34M |
| Operating Cash Flow | -12.78M | -11.45M | -12.61M | -20.04M | -12.34M | -17.33M |
| Investing Cash Flow | -137.62K | -7.50M | -5.72K | -36.46K | -89.15K | -10.47K |
| Financing Cash Flow | 44.09M | 39.67M | 9.22M | 124.34K | 16.30M | 36.69M |
Alterity Therapeutics Technical Analysis
Positive
3.55
Price Trends
3.42
Positive
3.39
Positive
4.02
Negative
Market Momentum
0.03
Negative
55.73
Neutral
80.44
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATHE, the sentiment is Positive. The current price of 3.55 is above the 20-day moving average (MA) of 3.46, above the 50-day MA of 3.42, and below the 200-day MA of 4.02, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 55.73 is Neutral, neither overbought nor oversold. The STOCH value of 80.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATHE.
Alterity Therapeutics Risk Analysis
Alterity Therapeutics disclosed 44 risk factors in its most recent earnings report. Alterity Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alterity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $168.59M | -34.52 | -111.37% | ― | ― | 66.05% | |
47 Neutral | $135.42M | -2.97 | -73.11% | ― | ― | 63.31% | |
46 Neutral | $61.47M | -2.07 | -30.19% | ― | ― | 63.85% | |
43 Neutral | $35.78M | -1.93 | -226.10% | ― | ― | 48.68% |
* Healthcare Sector Average
ATHE
Alterity Therapeutics
3.76
1.22
48.03%
CVM
Cel-Sci
4.23
-1.51
-26.29%
XBIT
XBiotech
2.29
-0.84
-26.84%
KLRS
Kalaris Therapeutics
6.46
-0.61
-8.63%
UNCY
Unicycive Therapeutics
6.68
1.98
42.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.